Background-The availability of implantable cardioverter-defibrillators (ICD) that are capable of antitachycardia pacing may lead to an increased use of ICDs in patients with haemodynamically tolerated ventricular tachycardia without a history of cardiac arrest. The frequency of potentially life-threatening fast ventricular tachycardias (cycle length < 250 ms) was investigated in patients who had a third generation ICD with endocardial leads implanted because they had haemodynamically tolerated ventricular tachycardia without a history of cardiac arrest.
Methods-Between January 1990 and October 1993, 50 patients (age (mean (SD)) 60 (11) ; ejection fraction 39 (16)%; 82% with coronary artery disease and 8% with dilated cardiomyopathy) with haemodynamically tolerated ventricular tachycardia (cycle length (mean (SD)) 348 (60) ms; range 250-500 ms) and without a history of cardiac arrest were treated with third generation ICDs that were capable of antitachycardia pacing. Fast ventricular tachycardia had been induced in 14 (28%) during baseline electrophysiological study. The benefit of ICD treatment was estimated as the difference between total mortality and the occurrence of fast ventricular tachycardia that would have been fatal if it had not been terminated. Results-During follow up of 17 (12) months, 33 patients (66%) had a total of 3861 episodes of ventricular tachycardia. 91% of these episodes were terminated by antitachycardia pacing. 11 patients (22%) had episodes of potentially life-threatening fast ventricular tachycardia and 3 of these also had inducible fast ventricular tachycardia. One patient died suddenly 27 months after implantation. The difference between survival without fast ventricular tachycardia and total mortality was 9%, 12%, 27%, and 27% at 6, 12, 18, and 24 months, respectively. Conclusions-About a fifth of patients who had been given an ICD to treat haemodynamically tolerated ventricular tachycardia and who had no history of cardiac arrest experienced fast ventricular tachycardia during follow up requiring immediate cardioversion. Prospective studies are needed to investigate whether the prognosis of patients with a history of haemodynamically tolerated ventricular tachycardia without cardiac arrest is improved by ICD therapy.
Implantable cardioverter-defibrillators (ICD) are widely used to prevent recurrent sudden cardiac death. In several studies the incidence of recurrent sudden death was reported to be remarkably low in patients with ICDs.1 3 Despite the lack of controlled trials implantation of an automatic cardioverter-defibrillator is now standard treatment for selected patients4-6 especially survivors of cardiac arrest. 7 In an earlier study we showed a substantial benefit from implantation of an automatic cardioverter-defibrillator in patients with refractory ventricular tachyarrhythmia.8 Most of these patients, however, had ventricular fibrillation or ventricular tachycardia that was not haemodynamically tolerated.
Recently, disappointing results with antiarrhythmic drugs9-1" and the introduction of automatic cardioverter-defibrillators with antitachycardia pacing modes have promoted the use of implantable cardioverter-defibrillators in patients with stable ventricular tachycardias without a history of cardiac arrest. This study was performed to analyse the potential impact of implantation of a third generation automatic cardioverter-defibrillator on mortality in patients with stable, haemodynamically tolerated ventricular tachycardia without a history of cardiac arrest.
Patients and methods

PATIENTS
We studied 50 consecutive patients with refractory, haemodynamically tolerated ventricular tachycardia without a history of cardiac arrest who had implantation of a third generation automatic defibrillator with endocardial defibrillation leads between January 1990 and October 1993 (table 1) . A haemodynamically tolerated and stable ventricular tachycardia was defined as a ventricular A non-thoracotomy approach was used in all patients. The electrode system used included a transvenous lead-subcutaneous patch system in 32 patients and a transvenous lead system in 18 patients (Cardiac Pacemakers Inc (CPI) Endotak or Medtronic Transvene). The devices used included the CPI Ventak PRx in 14 patients, the CPI Ventak PRxII in 11, the Ventitrex Cadence V-100 in two, the Medtronic PCD 7217B in 17, and the Medtronic PCD 7219D in six. Because all the devices used can store the intracardiac electrograms (n = 19) or RR intervals before and after the delivery of therapy (n = 31), the treated tachycardias could be classified.
ANTIARRHYTHMIC DRUG THERAPY
In 38 patients with ventricular tachycardia that was drug refractory, all class I or III antiarrhythmic agents were stopped immediately after we decided to implant an ICD. We waited for > 5 half lives of the last antiarrhythmic drug before an ICD was implanted. In patients who were taking amiodarone before implantation, a drug-free period of ) 10 days was required. Class I or III antiarrhythmic medication was continued to suppress frequent ventricular tachycardia in eight patients, to suppress supraventricular tachycardia that could lead to inappropriate ICD discharges in one, and to prolong tachycardia cycle length to allow antitachycardia pacing for termination of the tachycardia in three. In addition, 18 patients were treated with /3 blockers or digitalis to prolong atrioventricular conduction. During follow up, an antiarrhythmic regimen was changed only if frequent ventricular tachycardia could not be terminated by antitachycardia pacing or if a supraventricular tachycardia was detected.
FOLLOW UP All patients were followed up in the pacemaker clinic of our hospital every two months. They were instructed to phone the clinic in the event of a device discharge or syncope. Treated tachycardias were classified independently by two cardiologists. In patients with CPI Ventak PRxII devices all treated tachycardias were classified according to electrograms recorded from the defibrillation leads. In all patients with a Ventitrex Cadence V-100 or Medtronic PCD 7219D device treated tachycardias were classified according to the electrograms recorded from the sensing leads. In patients with devices that could not store electrograms (CPI Ventak PRx and Medtronic PCD 721 7B) tachycardias occurring out of the hospital were classified according to the cycle lengths recorded during treated episodes. Tachycardias were classified as VT/VF if the cycle length was < 290 ms or if the RR intervals were regular and the mean cycle length was significantly shorter than the programmed detection interval. All other treatments were classified as inappropriate.
We used the following end points: perioperative mortality (defined as death from any cause within 30 days after operation), sudden death (defined as either death within 1 h after the onset of initial symptoms or unwitnessed death), cardiac death, and total death. Recorded non-fatal events included ventricular tachyarrhythmias (of any rate) and fast ventricular tachyarrhythmias, arbitrarily defined as ventricular tachyarrhythmias with a cycle length < 250 ms before the first treatment by the device. In addition, the tachycardia cycle length had to be more than 50 ms shorter than the spontaneous tachycardia leading to implantation of the device. Because the only cycle lengths used to calculate the initial rate were those that occurred before the first treatment with the device, slow tachycardias that were accelerated by antitachycardia pacing were excluded from the analysis. Because there is evidence that surgery exacerbates ventricular tachyarrhythmias,'2 13 episodes occurring within seven days after operation were excluded from further analysis. Beyond this period, implantation of cardioverter defibrillators by itself does not exacerbate ventricular tachyarrhythmias.'2
We estimated the benefit of implantation of an automatic defibrillator by calculating the difference between total mortality and the occurrence of fast ventricular tachyarrhythmias, which we assumed would have been fatal without termination by the implanted defibrillator.
STATISTICAL METHODS
Mean, standard deviation, and range were used as indices of dispersion of the values observed. The log rank test was used to compare survival variables. A two-tailed probability value of < 0 05 was regarded as significant. Statistical analysis was performed with the SPSS for Windows program package (version 5.01) on an IBM AT computer.
Results
OPERATIVE RESULTS
During implantation we determined the defibrillation threshold (defined as the minimal energy required for termination of Epicardial leads were used in Kim et al's study whereas endocardial leads were used in our study.
BENEFIT FROM DEFIBRILLATOR IMPLANTATION
There is no consensus about the benefit from implantation of automatic defibrillators. Sweeney and Ruskin reviewed data sup-24 porting the contention that the implantable cardioverter-defibrillator prolongs survival. 20 Because most fast ventricular tachycardias are life threatening, the difference between total death rate and actuarial survival rate without fast ventricular tachyarrhythmia has been proposed as an estimate of the benefit of implantation of automatic defibrillators.A In our study, this difference suggests a substantial a-benefit from implantable cardioverter-defibril-;e lator implantation for patients with a history of of haemodynamically tolerated ventricular r-tachycardia without cardiac arrest because y-about a fifth of these patients developed fast of and immediately life-threatening ventricular as tachyarrhythmia during follow up. As might i-be expected, fast ventricular tachyarrhythmias st are less common in patients with a history of c-haemodynamically tolerated ventricular -y tachycardias than in the total group of patients with implantable cardioverter-defibrillators,8 which includes many survivors of cardiac arrests. Nevertheless, a substantial benefit from implantation of an automatic cardioverter-defibrillator was shown even in n-this group with a relatively low risk of sudden al death. The results accord with results mn reported for patients who received antitachyal cardia pacers without a defibrillation capabilal ity. Fisher We cannot exclude the possibility that some patients might have survived a fast ventricular tachycardia long enough to obtain medical attention. Another, less likely, source of possible overestimation of the benefit of implantable cardioverter-defibrillators is that some of the episodes of fast ventricular tachyarrhythmia might have been self terminated without the device discharging. However, patients who had self-terminating tachycardias before implantation of the device were treated with antiarrhythmic drugs to prevent this arrhythmia. In addition, in another study fast ventricular tachyarrhythmias showed no tendency to be self-terminating.
Another possibility is that the benefit of implantation of the device might have been underestimated because we included only those tachycardias that were fast from initiation in the analysis of the projected survival without the device. But many slow ventricular tachycardias degenerate into polymorphic ventricular tachycardia or ventricular fibrillation partly as a result of tachycardia induced 22 ischaemia.2
The possibility that the implantation of the ICD was arrhythmogenic and caused fast ventricular tachycardia in these patients who had never previously experienced a cardiac arrest is very unlikely. In an earlier study we showed that except in the immediate postoperative period the incidence of ventricular tachycardia episodes was not changed by the implantation procedure. We therefore excluded from further analysis episodes occurring within a week after implantation.
Antitachycardia pacing triggered by rapid atrial fibrillation or supraventricular tachycardia can induce ventricular tachycardia. Grimm The follow up period in our study was short, like that of other studies with second and third generation implantable cardioverter-defibrillators.'7 Although a longer follow up may be desirable, we were able to show a significant benefit of implantable cardioverter-defibrillator even within this short period. CLINICAL 
IMPLICATIONS
The results of our study suggest that implantation of automatic cardioverter-defibrillators should be considered not only in patients who have been resuscitated but also in patients with stable haemodynamically tolerated ventricular tachycardia without a history of cardiac arrest because many of these patients will develop fast ventricular tachyarrhythmias requiring immediate cardioversion.
Conclusions
Now that implantable cardioverter-defibrillators can have an antitachycardia pacing capability, device therapy has become a valuable alternative for the treatment of ventricular tachycardia even in patients without a history of cardiac arrest. Because some of these patients will develop primarily fast and immediately life-threatening ventricular tachycardia, they could benefit from the implantation of an automatic cardioverter-defibrillator. None the less, prospective controlled trials are needed before implantation of automatic cardioverter-defibrillators becomes an established clinical practice in patients who have not sustained a cardiac arrest. 
